Валеология: Здоровье, Болезнь, Выздоровление. 2021; : 69-75
АПЛАСТИЧЕСКАЯ АНЕМИЯ: ОБЗОР ЛИТЕРАТУРЫ
Аннотация
В обзоре представлены данные литературы, касающиеся вопросов изучения патогенеза и терапии, приобретенной апластической анемии (АА). Дан анализ сравнительной эффективности таких патогенетических стандартных методов лечения тяжёлой АА, как иммуносупрессивная терапия (ИСТ) и трансплантация костного мозга (ТКТ). Сделано заключение, что преимущества ИСТ заключаются в лёгкости её выполнения и доступности для всех пациентов, а недостаток в том, что она менее эффективна.
Список литературы
1. Issaragrisil S., Sriratanasatavom C., Piankijagum A. et al. Incidence of aplastic anemia in Bangkok. Blood 1991; 77: 2166-2168.
2. Bacigalupo A., Brand R., Oneto R. et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy: the European Group for Blood and Marrow Transplantation experience. Sem. Hematol. 2000; 37: 69-80.
3. Aplastic anemia: seed or soil (editorial). Lancet 1997; 8041: 748-750.
4. Solomou E. E., Rezvani K., Mielke S. et al. Deficient CD4 + CD25 + FOXP3 + T regulatory cells in acquired aplastic anemia. Blood 2007; 110:1603-1606.
5. Solomou E. E., Keyvanfar K., Young N. S. T-bet, a Thl transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006; 107: 3983-3991.
6. Young N. S., Calado R. T., Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.
7. Podesta M., Piaggio G., Frassoni F. et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy of bone marrow transplantation in severe aplastic anemia. Blood 1998; 91: 1959-1965.
8. Araten D. J., Nafa K., Pakdeesuvan K., Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 5209-5214.
9. Hertenstein B., Wagner B., Bunjes D. et al. Emergence of CD52~ phosphatidil inositol glycan anchor" deficient T lymphocytes after in vivo application of Campath 1H, for refractory B cell non-Hodgkin lymphoma. Blood 1995; 86: 1487-1492.
10. Sugimori C., Chuhjo T., Feng X. et al. Minor population of CD55" CD59~ blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107: 1308-1314.
11. Luzzato L., Bessler M., Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell 1997; 88: 1-4.
12. Locasciulli A., Oneto R., Bacigalupo A. et al. Severe Aplastic anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation (EBMT). Haematilogica 2007; 92: 11-18.
13. Camitta B., O'Reilly R. J., Sensenbrenner L. et al. Anyithoracic duct Lymphocyte globulin therapy of severe aplastic anemia. Blood 1983; 62: 883-888.
14. Bacigalupo A., Chaple M., Hows J. et al. Tratment of aplastic anemia (AA) with antilymphocyte globulin (ATG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br. J. Haematol. 1993; 83: 145-151.
15. Frickhofen N., Heimpel H., Kaltwasser G. P., Schrezenmeier H. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aolastic anemia. Blood 2003; 101: 1236-1242.
16. Viollier R., Passweg J., Gregor M. et al. Quality-adjusted survival analysis shows differences in outcome after immunosupression or bone marrow transplantation in aplastic anemia. Ann. Hematol. 2005; 84: 47-55.
17. Bacigalupo A., Bruno B., Saracco P. et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GIYMO / EBMT study on 100 patients. Blood 2000; 95: 1931-1934.
18. Di Bona E., Rodeghiero F., Bruno B. et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony ctimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br. J. Haematol. 1999; 107: 330-334.
19. Kojima S., Frickhofen N., Deeg H. J. et al. Aplastic anemia. Int. J. Hematol. 2005; 82: 408-411.
20. Saracco P., Quarello P., Lori A. P. et al. Cyclosporine response and cyclosporine dependence in children with acquired aplastic anemia treated with immunosupression: a multicentre retrospective study with long term observation follow up. Br. J. Haematol. 2008; 140: 197-205.
21. Schrezenmeier H., Marin P., Ragavachar A. et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from European Bone Marrow Transplantation Group SAA Working Party. Br. J. Haematol. 1993; 85: 371-377.
22. Teramura M., Kimura A., Iwase S. et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporine A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110: 1756-1761.
23. Тиганова О. А. Анализ результатов комбинированной иммуносупрессивной терапии приобретенной апластической анемии у детей: клинический опыт 10 лет работыгематологического отделения МДГКБ / О. А. Тиганова [и др.] – 2009. – 4: 41-46.
24. Tichelli A., Passweg J., Nissen S. et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anemia. Br. J. Haematol. 2002; 119: 1075-1082.
25. Bacigalupo A., Broccia G., Gordo G. et al. Antilymphocyte globulin, cyclosporine and granulocyte colony-stimulated factor in patients with acquired severe aplastic anemia (SAA): a pilot study at the EBMT SAA Working Party. Blood 1995; 85: 1348-1352.
26. Gluckman E., Rokicka-Milewska R., Hann I. et al. Results and follow-up of a phase III randomized study of recombinant human-granulocete stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br. J. Haematol. 2002; 119: 1075-1082.
27. Locasciulli A., Bruno B., Rambaldi A. et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony stimulating factor regimens: a GITMO prospective randomized study. Haematologica 2004; 89: 1054-1061.
28. Socie G., Mary J. Y., Schrezenmeier H. et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and marrow Transplantation (EBMT). Blood 1997; 109: 2794-2796.
29. Ohara A., Kojima S., Hamajima N. et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
30. Socie G., Henry-Amar M., Bacigalupo A. et al. Malignant tumors occurring after treatment of aplastic anemia. N. Engl. J. Med. 1993; 329: 1152-1157.
31. Kojima S., Matsuyama T., Kato S. et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799-803.
32. Bacigalupo A., Hows J., Gluckman E. et al. Bone marrow transplantation (BMT) versus immunosupression (IS) for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br. J. Haematol. 1988; 70: 177-179.
33. Tichelli A., Socie G., Marsh J. et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann. Intern. Med. 1999; 130: 193-201.
34. Tichelli A., Socie G., Marsh J. et al. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosupression. Ann. Intern. Med. 2002; 137: 164-172.
35. Schrezenmeier H., Passweg J. R., Marsh J. C. et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
36. Locatelly F., Bruno B., Zecca M. et al. Cyclosporin A and short-term methotrexate versus cyclosporine A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
37. George B., Methews V., Viswabandya A. et al. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant. 2007; 40: 13-18.
38. Deeg H. J., Amylon I. D., Harris R. E. et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol. Blood Marrow Transplant. 2001; 7: 208-215.
39. Миррахимов М. М. Гипо- и апластические анемии / М. М. Миррахимов, А. Р. Раимжанов, Н. Я. Юсупова. – В кн.: Лечение внутренних болезней горным климатом / Под. ред. М. М. Миррахимова. – Медицина,1977. – С. 92-132.
40. Раимжанов А. Р. Апластическая анемия и горный климат / А. Р. Раимжанов. – Бишкек, 2002. – С. 304 -3015.
Valeology: Health - Illnes - recovery. 2021; : 69-75
APLASTIC ANEMIA: LITERATURE REVIEW
Abstract
The review presents the literature data concerning the study of the pathogenesis and therapy of acquired aplastic anemia (AA). This analysis of the comparative effectiveness of such pathogenetic standard methods of treatment of severe AA as immunosuppressive therapy (IST) and bone marrow transplantation (TMT). It is concluded that the advantages of IST are the ease of its implementation and accessibility for all patients, and the disadvantages are that it is less effective.
References
1. Issaragrisil S., Sriratanasatavom C., Piankijagum A. et al. Incidence of aplastic anemia in Bangkok. Blood 1991; 77: 2166-2168.
2. Bacigalupo A., Brand R., Oneto R. et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy: the European Group for Blood and Marrow Transplantation experience. Sem. Hematol. 2000; 37: 69-80.
3. Aplastic anemia: seed or soil (editorial). Lancet 1997; 8041: 748-750.
4. Solomou E. E., Rezvani K., Mielke S. et al. Deficient CD4 + CD25 + FOXP3 + T regulatory cells in acquired aplastic anemia. Blood 2007; 110:1603-1606.
5. Solomou E. E., Keyvanfar K., Young N. S. T-bet, a Thl transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006; 107: 3983-3991.
6. Young N. S., Calado R. T., Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.
7. Podesta M., Piaggio G., Frassoni F. et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy of bone marrow transplantation in severe aplastic anemia. Blood 1998; 91: 1959-1965.
8. Araten D. J., Nafa K., Pakdeesuvan K., Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 5209-5214.
9. Hertenstein B., Wagner B., Bunjes D. et al. Emergence of CD52~ phosphatidil inositol glycan anchor" deficient T lymphocytes after in vivo application of Campath 1H, for refractory B cell non-Hodgkin lymphoma. Blood 1995; 86: 1487-1492.
10. Sugimori C., Chuhjo T., Feng X. et al. Minor population of CD55" CD59~ blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107: 1308-1314.
11. Luzzato L., Bessler M., Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell 1997; 88: 1-4.
12. Locasciulli A., Oneto R., Bacigalupo A. et al. Severe Aplastic anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation (EBMT). Haematilogica 2007; 92: 11-18.
13. Camitta B., O'Reilly R. J., Sensenbrenner L. et al. Anyithoracic duct Lymphocyte globulin therapy of severe aplastic anemia. Blood 1983; 62: 883-888.
14. Bacigalupo A., Chaple M., Hows J. et al. Tratment of aplastic anemia (AA) with antilymphocyte globulin (ATG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br. J. Haematol. 1993; 83: 145-151.
15. Frickhofen N., Heimpel H., Kaltwasser G. P., Schrezenmeier H. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aolastic anemia. Blood 2003; 101: 1236-1242.
16. Viollier R., Passweg J., Gregor M. et al. Quality-adjusted survival analysis shows differences in outcome after immunosupression or bone marrow transplantation in aplastic anemia. Ann. Hematol. 2005; 84: 47-55.
17. Bacigalupo A., Bruno B., Saracco P. et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GIYMO / EBMT study on 100 patients. Blood 2000; 95: 1931-1934.
18. Di Bona E., Rodeghiero F., Bruno B. et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony ctimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br. J. Haematol. 1999; 107: 330-334.
19. Kojima S., Frickhofen N., Deeg H. J. et al. Aplastic anemia. Int. J. Hematol. 2005; 82: 408-411.
20. Saracco P., Quarello P., Lori A. P. et al. Cyclosporine response and cyclosporine dependence in children with acquired aplastic anemia treated with immunosupression: a multicentre retrospective study with long term observation follow up. Br. J. Haematol. 2008; 140: 197-205.
21. Schrezenmeier H., Marin P., Ragavachar A. et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from European Bone Marrow Transplantation Group SAA Working Party. Br. J. Haematol. 1993; 85: 371-377.
22. Teramura M., Kimura A., Iwase S. et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporine A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110: 1756-1761.
23. Tiganova O. A. Analiz rezul'tatov kombinirovannoi immunosupressivnoi terapii priobretennoi aplasticheskoi anemii u detei: klinicheskii opyt 10 let rabotygematologicheskogo otdeleniya MDGKB / O. A. Tiganova [i dr.] – 2009. – 4: 41-46.
24. Tichelli A., Passweg J., Nissen S. et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anemia. Br. J. Haematol. 2002; 119: 1075-1082.
25. Bacigalupo A., Broccia G., Gordo G. et al. Antilymphocyte globulin, cyclosporine and granulocyte colony-stimulated factor in patients with acquired severe aplastic anemia (SAA): a pilot study at the EBMT SAA Working Party. Blood 1995; 85: 1348-1352.
26. Gluckman E., Rokicka-Milewska R., Hann I. et al. Results and follow-up of a phase III randomized study of recombinant human-granulocete stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br. J. Haematol. 2002; 119: 1075-1082.
27. Locasciulli A., Bruno B., Rambaldi A. et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony stimulating factor regimens: a GITMO prospective randomized study. Haematologica 2004; 89: 1054-1061.
28. Socie G., Mary J. Y., Schrezenmeier H. et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and marrow Transplantation (EBMT). Blood 1997; 109: 2794-2796.
29. Ohara A., Kojima S., Hamajima N. et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
30. Socie G., Henry-Amar M., Bacigalupo A. et al. Malignant tumors occurring after treatment of aplastic anemia. N. Engl. J. Med. 1993; 329: 1152-1157.
31. Kojima S., Matsuyama T., Kato S. et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799-803.
32. Bacigalupo A., Hows J., Gluckman E. et al. Bone marrow transplantation (BMT) versus immunosupression (IS) for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br. J. Haematol. 1988; 70: 177-179.
33. Tichelli A., Socie G., Marsh J. et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann. Intern. Med. 1999; 130: 193-201.
34. Tichelli A., Socie G., Marsh J. et al. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosupression. Ann. Intern. Med. 2002; 137: 164-172.
35. Schrezenmeier H., Passweg J. R., Marsh J. C. et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
36. Locatelly F., Bruno B., Zecca M. et al. Cyclosporin A and short-term methotrexate versus cyclosporine A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
37. George B., Methews V., Viswabandya A. et al. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant. 2007; 40: 13-18.
38. Deeg H. J., Amylon I. D., Harris R. E. et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol. Blood Marrow Transplant. 2001; 7: 208-215.
39. Mirrakhimov M. M. Gipo- i aplasticheskie anemii / M. M. Mirrakhimov, A. R. Raimzhanov, N. Ya. Yusupova. – V kn.: Lechenie vnutrennikh boleznei gornym klimatom / Pod. red. M. M. Mirrakhimova. – Meditsina,1977. – S. 92-132.
40. Raimzhanov A. R. Aplasticheskaya anemiya i gornyi klimat / A. R. Raimzhanov. – Bishkek, 2002. – S. 304 -3015.
